In order to further guide drug marketing authorization holders to revise the safety information items in package inserts of marketed traditional Chinese medicines, strengthen life cycle management of traditional Chinese medicines and guarantee the drug safety for the public, NMPA organized to formulate the Technical Guideline for the Revision of Safety Information Items in Package Inserts of Marketed Traditional Chinese Medicines (Interim), which was issued on January 4, 2022.